Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 41,338 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 41,338 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $544,421.46. Following the completion of the sale, the insider directly owned 427,775 shares in the company, valued at approximately $5,633,796.75. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Adaptive Biotechnologies Trading Up 5.8%

Shares of ADPT stock opened at $13.17 on Friday. The firm’s 50 day moving average is $16.55 and its 200 day moving average is $15.85. The stock has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) EPS. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies in the fourth quarter valued at approximately $28,000. Sound Income Strategies LLC purchased a new position in Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. raised its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at $51,000. 99.17% of the stock is currently owned by institutional investors.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of recent analyst reports. Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.